Medincell (MDCLF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hi everyone and thank you for joining us today for this conference following the release of our half-year results which were published earlier today. The press release is available on our website. Today I'm joined by Christophe Douat, our CEO. Hi, Christophe. Hi, David. Dr. Richard Malamud, our CMO. Hi, Richard. Hi, David. And by Stéphane Postic, our CFO. Hi, Stéphane. Hi, David. Hi, everyone. Before we start, I invite you to review the forward-looking statements disclaimer at the beginning of the presentation available on our website. This webcast will last 45 minutes max. We start with the presentation and by a Q&A session if we receive questions. You can send your questions at any time using the chat tool on the right side of your screen. A similar session in French was held earlier, and both replays will be available shortly on our website. But now, I leave the floor to you, Christophe. Thank you, David. Hello, everybody. We are delighted to have you join us and celebrate the filing of Orlan Zapin LAI. It's a major event for the company. So lots of emotions and excitation at Medincelle today. Last June, I told you that Medincelle was entering the most transformative years of its history, mostly thanks to Oranzapine. And here we are. Our partner, Teva, filed the Oranzapine LAI application. at the FDA today. And so the clock will start clicking since FDA has 10 months to get back to Teva with the potential approval sometime in the Q4 of 26 for a product that is a major product, a priority product. at our partner, and of course, a priority at Made in Cell. So, let me remind you of our strategy shift to growth. You can see that UZD, and we'll come back to UZD in a second, is the first engine of growth of Made in Cell. Olanzapine will accelerate growth, and then the t...